More articles from Preclinical Probes for Oncology

You have access
PET imaging of PD-L1 using anti-PD-L1-B11 antibody in breast cancer tumor model
Aditya Bansal, Whitney Barham, Xin Liu, Susan Harrington, Fabrice Lucien-Matteoni, Haidong Dong, Sean Park, Mukesh Pandey and Timothy DeGrado

Journal of Nuclear Medicine May 1, 2021, 62 (supplement 1) 1486;
You have access
^99mTc-HYNIC-diabody targeting transferrin receptor for tumor imaging
Yong He and Lei Dai

Journal of Nuclear Medicine May 1, 2021, 62 (supplement 1) 1502;
You have access
PET Imaging and Biodistribution of ⁶⁴Cu-DOTA-Atezolizumab in Mice Bearing MDA-MB231 Xenograft
Vinod Nagarajan, Seri Park, Deok Il Kim, Sang-Keun Woo and ILHAN LIM

Journal of Nuclear Medicine May 1, 2021, 62 (supplement 1) 1490;
You have access
Preclinical assessment of nanoparticles conjugated with ⁶⁴Cu-DOTA-PEG-BBN targeting gastrin-releasing peptide receptors
Livia Elena Chilug, Alexandrina Nan, Radu Anton Leonte, Ramona Daniela Dusman, Antero Abrunhosa, Gina Manda, Rodica Turcu and Dana Niculae

Journal of Nuclear Medicine May 1, 2021, 62 (supplement 1) 1508;
You have access
Chelator free Ga-68/Gd co-labeling ultra-small gold nanorod for colorectal cancers PET-MRI diagnosis and image-guided radiotherapy
Lu Zhang and Changjing Zuo

Journal of Nuclear Medicine May 1, 2021, 62 (supplement 1) 1488;
You have access
Initial biological evaluations of [18F]KS1, ascorbate-based ROS imaging ligand in tumor models of non-human primates.
Naresh Damuka, Greg Dugan, Ashley Davis, Buddhika Liyana Pathirannahel, John Puckett, Michael Moore, Gagan Deep, Avinash Bansode, Akiva Mintz, Cristina Furdui, Mark Cline and Kiran Kumar Solingapuram Sai

Journal of Nuclear Medicine May 1, 2021, 62 (supplement 1) 1480;
You have access
Indium-111-labeled Dual CA9-targeted Probe as a Potential Nuclear Imaging Agent for Hypoxic Colorectal Cancer Detection in a Xenograft Mouse Model
Siao Syun Guan, Tse-Zung Liao, Kun-Liang Lin, Cheng-Liang Peng and Tsai-Yueh Luo

Journal of Nuclear Medicine May 1, 2021, 62 (supplement 1) 1472;
You have access
Development of a carbon-11 labeled thienopyrimidine based radioligand for EGFR-tyrosine-kinase-inhibitor (TKI) specific PET imaging of glioblastoma
Yngve Guttormsen, Angel Moldes-Anaya, Richard Fjellaksel, Ana Oteiza, Montserrat Martin-Armas, Marcel Lindemann, Julia Bihler, Bard Helge Hoff, Steen Jakobsen, Eirik Sundby, Rune Sundset and Mathias Kranz

Journal of Nuclear Medicine May 1, 2021, 62 (supplement 1) 1476;
You have access
Development of In-111-labeled niosomes for evaluation of pharmacokinetics of the niosomes
Masayuki Munekane, Asami Kosugi, Kento Kannaka, Kohei Sano, Toshihide Yamasaki, Ken-ichi Ogawara and Takahiro Mukai

Journal of Nuclear Medicine May 1, 2021, 62 (supplement 1) 1467;
You have access
Preclinical evaluation of PSMA-TO1- a PSMA-targeting ligand with increased circulating half-life
Catherine Meyer, Andreea Stuparu, Katharina Lueckerath, Lea Nyiranshuti, Johannes Czernin, Magnus Dahlbom, Jeremie Calais and Roger Slavik

Journal of Nuclear Medicine May 1, 2021, 62 (supplement 1) 1504;

Main menu

User menu

Search

More articles from Preclinical Probes for Oncology

Pages